| October 1 |
Vertex Announces Publication of Abstracts for Presentation at 58th
AASLD Meeting |
| October 1 |
Regeneron Announces Positive Primary Endpoint Results from a Phase
2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration |
| October 1 |
Orexo Shows Positive Results in Completed Comparative Phase III
Profile Study of the Sublinox Sleep Aid Involving Insomnia Patients |
| October 1 |
ChemGenex Announces Positive Preliminary Data From Phase 2/3
Clinical Trial of Ceflatonin(R) at International Conference |
| October 1 |
Addex Pharmaceuticals Announces ADX10061 Phase IIa Smoking
Cessation Data |
| October 1 |
Theratechnologies Reports Positive 52-Week Phase 3 Results for Its
Lead Drug Candidate Tesamorelin |
| October 1 |
Webcast Alert: Isis Pharmaceuticals Discusses its New ISIS 301012
Phase 2 Clinical Data Presented at the DALM Symposium |
| October 1 |
Abbott's ABT-874 Shows Positive Results for Maintenance of Response
in Phase II Psoriasis Study |
| October 1 |
Macusight Announces Positive Initial Results from Phase 1 Study of
Sirolimus in Diabetic Macular Edema |
| October 1 |
MacuSight Announces Positive Initial Results From Phase 1 Study of
Sirolimus in Diabetic Macular Edema |
| October 1 |
FASgen Announces Significant Milestone in Its Cancer Drug
Development Program |
| October 1 |
ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical
Trial of ANX-510 (Cofactor) |
| October 2 |
Vaginal Progesterone Gel May Improve Infant Outcomes and Reduce the
Rate of Preterm Birth in Women with a Short Cervix in Mid-Pregnancy |
| October 2 |
NicOx and Ferrer Present Promising Clinical and Preclinical Results
in Dermatology |
| October 2 |
Adventrx Pharmaceuticals Announces Results From Phase 2b Clinical
Trial of ANX-510 (CoFactor) |
| October 2 |
Introgen Announces Publication of Research Showing Promising
Activity of INGN 241 Combined with Velcade in Ovarian Cancer |
| October 2 |
CardioVascular BioTherapeutics Completes Phase I Wound Healing
Trial |
| October 2 |
Advanced Life Sciences to Present Data from Selected Cethromycin
Clinical Trials at the 45th Annual Meeting of the Infectious
Diseases Society of America |
| October 2 |
Lu AA21004 Shows Highly Significant Results in Clinical Phase II
Trial |
| October 2 |
Introgen Announces Publication of Research Showing Activity of INGN
241 Combined with Velcade |
| October 2 |
HemoBioTech's CEO, Arthur Bollon, Ph.D., to Present at The
NanoTX'07 Conference and Expo |
| October 3 |
Inspire Announces Poster Presentations at the 2007 North American
Cystic Fibrosis Conference |
| October 3 |
Threshold to Host Conference Call to Discuss Results From Clinical
Presentations at European Cancer Conference (ECCO) |
| October 3 |
New Data Reveal Topical Divigel (estradiol gel) 0.1% Significantly
Reduces Frequency and Severity of Hot Flashes |
| October 3 |
Upstream Biosciences CEO to Unveil Promising New Approach to
Treating Sleeping Sickness at International Trypanosomiasis
Conference |
| October 3 |
Crucell presents Phase I results rabies antibody cocktail showing
safety and ability to protect |
| October 3 |
Promising Phase 3 Trial Results Show Novel Biologic Therapy
Ustekinumab (CNTO 1275) Significantly Improved Psoriasis |
| October 3 |
Carrington Subsidiary DelSite to Present at International Vaccine
Conference in Ireland |
| October 3 |
Depressed Adolescents Respond Best to Combination Treatment |
| October 4 |
Early Stage Drug Shows Promise Against Cancer Cells from Young
Patients |
| October 4 |
Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in
Heterozygous FH Patients |
| October 4 |
BioSante Pharmaceuticals To Present Validation Data Required for
Development of LibiGel (transdermal testosterone gel) in the
Treatment of Female Sexual Dysfunction |
| October 4 |
Hollis-Eden Pharmaceuticals Presents Positive Results with Novel
Drug Candidate HE3235 in Model of Hormone Independent Prostate
Cancer |
| October 4 |
Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease |
| October 4 |
TB4 Triggers Adult Stem Cells to Form New Blood Vessels and Repair
Heart Tissue - Reports U.K. Scientist |
| October 4 |
Advaxis' John Rothman to Present Phase I Data at the World Vaccine
Congress 2007 |
| October 4 |
Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM |
| October 4 |
BioSante Pharmaceuticals To Present Validation Data Required for
Development of LibiGel (transdermal testosterone gel) in the
Treatment of Female Sexual Dysfunction |
| October 4 |
Gilead Announces Detailed Results of Phase III Study of Aztreonam
Lysine for Inhalation in Patients With Cystic Fibrosis |
| October 4 |
Salix Announces Statistically Significant Top- Line Results for
Second Product Registration Study of Granulated Mesalamine in
Ulcerative Colitis |
| October 4 |
MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and
National RSV Surveillance Results |
| October 4 |
Thallion to Present ECO-4601 Human Pharmacokinetic Data at
AACR-NCI-EORTC Conference |
| October 5 |
Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated
for Five Or More Months |
| October 5 |
Heart Failure Patient Recovers After Cellmedicine Adult Stem Cell
Therapy |
| October 5 |
Bayhill Therapeutics to Present Positive Data From a Phase IIb
Trial of BHT-3009 in Multiple Sclerosis |
| October 5 |
Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II
Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism
(DALM) 2007 Conference |
| October 5 |
Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib),
Produced Positive Effects on Lipids with No Observed Blood Pressure
Changes in Phase IIb Study |
| October 5 |
OXiGENE Reports Positive Interim Results from Phase Ib Zybrestat -
Bevacizumab Combination Study in Advanced Solid Tumors |
| October 5 |
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on
SLx-4090 at The 16th International Symposium on Drugs Affecting
Lipid Metabolism |
| October 5 |
Karo Bio Presents Positive KB2115 Phase IIa Proof of Concept Data
at Two Major Scientific Meetings |
| October 5 |
Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib),
Produced Positive Effects on Lipids with No Observed Blood Pressure
Changes in Phase IIb Study |
| October 5 |
New Data Presented on Immunocytokine Fusion Protein Further
Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS
Technology Platform |
| October 5 |
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on
SLx-4090 |
| October 5 |
Interim Results from a New Trial of Cancidas (caspofungin acetate)
in Pediatric Patients with Documented Fungal Infections |
| October 5 |
PTC Therapeutics Announces Encouraging Additional Phase 2 Results
of PTC124 in Cystic Fibrosis |
| October 5 |
Tryton Medical's Side-Branch Stent Demonstrates Unparalleled 6
Month Angiographic Restenosis Reduction |
| October 8 |
Alnylam Presents First Ever Non-Human Primate Data with an RNAi
Therapeutic Targeting PCSK9 Showing Significant and Durable
Reductions in LDL Cholesterol Levels |
| October 8 |
Hollis-Eden Pharmaceuticals Presents Positive Data Demonstrating
HE3286 Provides Benefit in Animal Model of Ulcerative Colitis |
| October 8 |
Neupro (Rotigotine Transdermal System) Effective in Controlling
Early Morning Motor Impairment and Generally Well-Tolerated for
Long-Term Use in Patients with Parkinson's Disease |
| October 8 |
Rotigotine Transdermal System Shows Significant Symptom Reduction
and Tolerability in Patients with Restless Legs Syndrome |
| October 8 |
Isis Favorably Revises Financial Guidance and Introduces Mipomersen
as Generic Name for ISIS 301012 |
| October 8 |
American and European Parkinson's Sufferers Find Chinese Stem Cell
Treatment Effective, Proving Western Debates Moot |
| October 8 |
The International Myeloma Foundation Says New Thalidomide Data
Confirms Survival Benefits for Older Patients |
| October 8 |
Isis Reports Preclinical Data Supporting Liver Safety of ISIS
301012 |
| October 8 |
Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for
NDA Filing of Bazedoxifene/Conjugated Estrogens |
| October 8 |
Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at
the 2007 AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics |
| October 8 |
Leading Medical Experts Call for More Effective Strategies to
Address Clostridium difficile-Associated Disease |
| October 8 |
Noven Announces Results of Phase 3 Clinical Study of Once-Daily
Lithium Product |
| October 8 |
Topline Findings from Comparative Analysis of Invega and Quetiapine
in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric
and Mental Health Congress |
| October 8 |
Metabasis Therapeutics Presents Preclinical Results for MB07811,
Its Novel Product Candidate for the Treatment of Hyperlipidemia at
the American Thyroid Association's National Meeting |
| October 8 |
New Data Show Ceftobiprole as Effective as Combination Therapy in
Treating Patients with Diabetic Foot Infections |
| October 8 |
21st World Congress of Dermatology Highlights Clinical Significance
of Photodynamic Therapy |
| October 8 |
Neupro (Rotigotine Transdermal System) Effective in Controlling
Early Morning Motor Impairment and Generally Well-Tolerated for
Long-Term Use in Patients with Parkinson's Disease |
| October 8 |
MediciNova Will Announce Clinical Results From a Phase IIa Clinical
Study for MN-221, a Novel Treatment for Status Asthmaticus, On
Tuesday, October 9, 2007 At 3:00 a.m. Eastern Time |
| October 9 |
Vical Demonstrates Dose-Sparing of Protein-Based H5N1 Influenza
Vaccine With Vaxfectin Adjuvant |
| October 9 |
New Study by ARIAD Scientists Offers Insights into Design of
Small-Molecule Drugs to Treat Drug-Resistant Leukemia |
| October 9 |
Sirtris Pharmaceuticals' Oral Drug Candidate SRT501 Shown to be
Neuroprotective: Implications for SIRT1 Activation in
Neurodegenerative Eye Disorders |
| October 9 |
Arpida Presents Additional Data on iclaprim at IDSA |
| October 9 |
MediciNova Reports Positive Phase IIa Clinical Study Results for
MN-221, a Novel Treatment for Status Asthmaticus |
| October 9 |
Arpida Presents Additional Data on Iclaprim at IDSA |
| October 9 |
New Publication Report -- Hyperthermia Plus Cisplatin as a
Treatment for Recurrent Cervical Carcinoma for Previously
Irradiated Patients |
| October 9 |
New Data for XL880, XL647 and XL184 to Be Presented at
AACR-NCI-EORTC |
| October 9 |
Cautious Optimism for New Alzheimer's Medications, Reports the
Harvard Mental Health Letter |
| October 9 |
orBec Clinical Summary Published in "Expert Opinion on
Investigational Drugs" |
| October 9 |
One Shot of Gene Therapy Spreads Through Brain in Animal Study |
| October 9 |
Amorfix Life Sciences develops two vaccines that extend life in
Amyotrophic Lateral Sclerosis (ALS) animal model |
| October 9 |
Advaxis, Inc. Phase I/II Results of Lovaxin C in Cervical Cancer
Study Released |
| October 9 |
Antibody Leads to Repair of Myelin Sheath in Lab Study of Multiple
Sclerosis and Related Disorders, Mayo Clinic Study Shows |
| October 10 |
Applied Biosystems Offers Commentary About Discovery of Increased
Genetic Variation in Human Genome |
| October 10 |
Kiadis Pharma Announces ATIR Interim Clinical Results |
| October 10 |
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102
(PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at
Upcoming AACR-NCI-EORTC International Conference |
| October 10 |
AMAG Pharmaceuticals, Inc. Announces Eight Abstracts on Ferumoxytol
to Be Presented at Upcoming American Society of Nephrology Meeting |
| October 10 |
Emergent BioSolutions' Typhoid Vaccine Candidate Achieves Endpoints
in Phase II Clinical Study |
| October 10 |
Advitech Announces Positive Preclinical Results for Wound-Healing
Application |
| October 10 |
Analysis Shows Vernakalant Hydrochloride Injection Increases
Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation
Patients Treated Within 48 Hours of Onset |
| October 10 |
Data Show Vaprisol Is Effective & Safe in Promptly Increasing
Serum Sodium Levels in Patients With Euvolemic or Hypervolemic
Hyponatremia |
| October 10 |
Ligand Research Published in Journal of Medicinal Chemistry:
LGD-2941 Shows Promise in Treating Muscle and Bone Loss |
| October 10 |
Multicenter PolyHeme Trauma Study Presented at the American College
of Surgeons 93rd Annual Clinical Congress |
| October 11 |
Clinical Benefits Demonstrated with Low-Dose Gattex in Phase 3
Short Bowel Syndrome Study |
| October 11 |
Pro-Pharmaceuticals Reports 43% Response Rate in Colorectal Trial |
| October 11 |
CuraGen Announces Top-Line Phase II Results on Velafermin |
| October 11 |
Iomai Chief Scientific Officer Dr. Gregory Glenn Details
Development of Travelers' Diarrhea Patch at Keystone Conference |
| October 11 |
Pluristem to Present Promising PLX Data for Additional Clinical
Indications at Prestigious International Conference on Regenerative
Medicine |
| October 11 |
Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline
Presentations at the European Committee for Treatment and Research
of Multiple Sclerosis |
| October 11 |
VIVUS Announces Qnexa Abstract Presentation at the 7th
International Congress on Coronary Artery Disease |
| October 11 |
KineMed Presents Preclinical Data for Investigational Agent
Demonstrating Neurogenesis and Confirming Improvements in
Behavioral Model |
| October 11 |
Researchers Report First Successful Treatment of Chronic Traumatic
Brain Injury |
| October 11 |
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of
CD-NP, a Selective NPR-B Agonist in Clinical Development for the
Treatment of Heart Failure |
| October 11 |
Nymox Announces New BPH Drug Long Term Follow-up Study Clinical
Data Presentation October 20 at American Urological Association
Meeting |
| October 11 |
Ligand Research Published in Journal of Medicinal Chemistry:
LGD-2941 Shows Promise in Treating Muscle and Bone Loss |
| October 11 |
Genzyme and Bayer Schering Pharma AG, Germany to Present New Data
on Alemtuzumab in Multiple Sclerosis at ECTRIMS |
| October 11 |
New Tysabri Data to Be Presented at the European Committee for
Treatment and Research in Multiple Sclerosis |
| October 12 |
OctoPlus announces positive Phase IIa efficacy and tolerability
results for Locteron in hepatitis C |
| October 12 |
BioXell announces positive Phase IIb results for Elocalcitol in
Benign Prostatic Hyperplasia |
| October 12 |
New Preclinical Data Suggests FTY720 May Repair or Reduce Damage
Caused by Multiple Sclerosis Through a Direct Effect in the Brain |
| October 12 |
Cougar Biotechnology Presents Positive CB7630 Phase II Data at
Prostate Cancer Foundation Scientific Retreat |
| October 12 |
Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial |
| October 12 |
Resverlogix is Presenting at IAS HDL Workshop |
| October 12 |
Long-Term Study Shows Copaxone Significantly Slows Progression of
Disability and Reduces Relapse Rates in Patients with
Relapsing-Remitting Multiple Sclerosis |
| October 12 |
PTC Therapeutics Announces Pharmacokinetic and Safety Results from
Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy |
| October 12 |
Phase 2 Data Show Daclizumab Significantly Reduced Multiple
Sclerosis Lesions in Patients Receiving Interferon Beta Therapy |
| October 12 |
New Data Suggests Progression of Disability at Two Years Predicts
Multiple Sclerosis (MS) Disability Progression at Eight Years |
| October 12 |
New Preclinical Data Suggests FTY720 May Repair or Reduce Damage
Caused by Multiple Sclerosis Through a Direct Effect in the Brain |
| October 15 |
Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM
1003 in Alzheimer's Disease |
| October 15 |
BioMS Medical Presents at the 23rd Congress of the European
Committee for Treatment and Research in Multiple Sclerosis |
| October 15 |
Invega Significantly Reduced Symptoms of Schizophrenia Compared to
Seroquel in Acutely Ill, Hospitalized Patients |
| October 15 |
Review of Probiotic Trial Research Finds Only Bifantis Able to
Claim Efficacy versus Placebo for IBS Symptoms |
| October 15 |
Improved Perioperative Blood Pressure Control Associated with
Reduced Risk of Kidney Dysfunction in Cardiac Surgery Patients |
| October 15 |
Sucampo Pharmaceuticals Presents Data on Cobiprostone at American
College of Gastroenterology Annual Scientific Meeting |
| October 15 |
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab
in Multiple Sclerosis |
| October 15 |
Betaferon Long-term Study Shows That Early Disability in MS
Patients Predicts Later Cognitive Decline |
| October 15 |
Aloxi Phase 3 Data for Post Operative Nausea and Vomiting (PONV)
Presented at the Annual Meeting of the American Society of
Anesthesiologists (ASA) |
| October 15 |
Antisoma Encouraged by ASA404 Prostate Cancer Data |
| October 15 |
Clinical Studies Show Remicade Reduces Incidence of Bowel Surgeries
in Ulcerative Colitis Patients |
| October 15 |
Leuchemix Announces Publication of Data On Its Lead Cancer Drug
Candidate |
| October 15 |
Xanthus Presents Data from FLT3 Autoimmune Program Supporting Novel
Cell-targeted Mechanism for Disease Attenuation |
| October 15 |
BioMS Medical Presents at the 23rd Congress of the European
Committee for Treatment and Research in Multiple Sclerosis |
| October 15 |
Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in
Phase 1B Study |
| October 15 |
Study Data Results Showed Desvenlafaxine Significantly Reduced
Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus
Placebo |
| October 15 |
New Analysis of Study Data Shows That Asacol (Mesalamine) Delivers
Rapid Symptom Relief for Ulcerative Colitis Patients |
| October 15 |
Vaginal Progesterone is Equally Effective and Results in Lower
Miscarriage Rates Than Injectable Progesterone in Infertility
Treatment |
| October 15 |
New Analyses of Long-Term Lialda (mesalamine) Data Presented at ACG |
| October 15 |
Celera and Collaborators Identify a Five-Gene Genetic Risk Score
That Predicts Risk of Coronary Heart Disease |
| October 15 |
Valdoxan, the First Melatonergic Antidepressant, Confirms its
Efficacy in Preventing Relapse Whatever the Severity of the
Depression |
| October 15 |
Alpharma Presents Positive Results From a Phase 2 Study of the
Investigational Abuse-Deterrent Opioid ALO-01 |
| October 15 |
ACG: Study Finds that Asacol Can Provide Faster Symptom Relief |
| October 15 |
Ocera Therapeutics Announces Positive Results with AST-120 in
Pouchitis |
| October 16 |
Evotec Reports Positive Top-Line Results in Phase II Study With EVT
201 in Elderly Insomniacs With Daytime Sleepiness |
| October 16 |
Rigel to Present Research Programs at Scientific Conferences |
| October 16 |
Anesiva Announces Pivotal Phase 3 Trial of Zingo Meets Primary
Endpoint and Significantly Reduces Venous Access Pain in Adults |
| October 16 |
Arius Highlighted at AACR-NCI-EORTC 2007 International Cancer
Conference |
| October 16 |
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in
Patients With Proteinuria Associated With Diabetic Nephropathy |
| October 16 |
Evotec Reports Positive Top-Line Results in Phase II Study with EVT
201 in Elderly Insomniacs with Daytime Sleepiness |
| October 16 |
Forest Laboratories, Inc. and Gedeon Richter Announce Results of
Phase II-B Study for RGH-188 as a Treatment for Schizophrenia |
| October 16 |
XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007 |
| October 16 |
Nereus Pharmaceuticals' NPI-0052 Named One of the Industry's Top
Ten Unpartnered Oncology Drug Candidates |
| October 16 |
Lexicon Reports Initial Clinical Trial Results for LX1031, an
Investigational New Drug for Irritable Bowel Syndrome |
| October 16 |
New Study Shows Listeria Vaccine for Cervical Cancer Found Safe |
| October 16 |
Data from Three Clinical Trials for Perforomist Inhalation Solution
to be Presented at CHEST 2007 on October 24, 2007 |
| October 16 |
New Data Suggests Doctors Might Not Be Considering Depression
Symptoms That Are Important to Patients, Such as Pain and Anxiety |
| October 16 |
Studies Show Body Mass Index Has No Effect on Resolution and
Healing of GERD Symptoms |
| October 16 |
Fish Get Insomnia, Eyes Wide Open, Say Stanford Sleep Researchers |
| October 16 |
New Data Published in Neurology Show Once-Daily Lamictal XR
Significantly Reduced Partial Seizures in Patients with Epilepsy |
| October 16 |
Cimzia Demonstrates Sustained Long-Term Efficacy and Favorable
Tolerability in the Treatment of Crohn’s Disease at Stable
Doses |
| October 16 |
Achillion Reports Safety and Potent Antiviral Activity in Topline
Results From Elvucitabine Phase 2 Study in HIV-Infected Patients |
| October 16 |
Sugammadex Trials Demonstrate Rapid Recovery from Profound
Neuromuscular Blockade During General Anesthesia |
| October 16 |
Webcast Alert: Aastrom Announces Conference Call to Discuss the
Results from the U.S. Phase I/II Severe Fracture Trial |
| October 16 |
MedImpact Study Highlights Treatment Challenges Among Those
Suffering from Hypertension |
| October 17 |
Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics |
| October 17 |
Curis Announces Presentation at CHI's ''Discovery on Target:
Developing Inhibitors for Promising Drug Targets'' Conference |
| October 17 |
Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania
Symptoms for the Treatment of Bipolar I Disorder |
| October 17 |
Omiganan Phase II Rosacea Study Demonstrates Promising Results |
| October 17 |
Alnylam and Collaborators Publish New Pre-clinical Results on RNAi
Therapeutics for the Treatment of Huntington's Disease |
| October 17 |
Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle
Spasticity and Rigidity in Preclinical Study Conducted at
University of California, San Diego |
| October 17 |
Cordis Corporation Announces Clinical Studies and Events at TCT
2007 |
| October 17 |
Boston Scientific to Release Broad Range of Clinical Trial Data
Reinforcing Safety and Efficacy of Taxus Coronary Stent Systems at
TCT 2007 |
| October 17 |
New Mircera Data Analyses to be Featured at the American Society of
Nephrology Annual Meeting |
| October 17 |
SuperGen to Highlight Oncology Pipeline Data in Multiple
Presentations at the AACR-NCI-EORTC International Conference |
| October 17 |
Pro-Pharmaceuticals Novel Carbohydrate Compounds Reverse Liver
Fibrosis in Pre-clinical Studies |
| October 17 |
Avalon Pharmaceuticals to Present on Its Beta-catenin and c-Myc
Pathway Inhibitor Programs at the AACR-NCI-EORTC 2007 International
Conference |
| October 17 |
OMRIX Biopharmaceuticals Announces Positive Phase I Results with
Fibrin Patch |
| October 17 |
Cell Therapeutics, Inc. (CTI) to Sponsor Conference in Italy on
Women, Smoke and Lung Cancer |
| October 17 |
Accentia Announces Results of Market Survey on Chronic Sinusitis
Based on Responses From 750 ENT Specialists |
| October 17 |
Scientists Show Monoclonal Antibody Leads to Repair of Myelin
Sheath in Laboratory Study of Multiple Sclerosis |
| October 17 |
Cordis Corporation Announces Clinical Studies And Events At TCT
2007 |
| October 17 |
Agencourt Genomic Services is Key Collaborator in New Research That
Further Defines Landscape of Breast and Colon Cancers |
| October 17 |
Aethlon Medical Releases Ebola & Marburg Treatment Report |
| October 17 |
Study Finds Anti-Convulsant Drug Decreases Pain, Expedites Movement
in Knee Replacement Patients |
| October 17 |
Results of Colon Cancer Study Utilizing Pressure Cycling Technology
(PCT) Presented at the American College of Gastroenterology Annual
Scientific Meeting |
| October 17 |
Molecular Biometrics Reports IVF Breakthrough at ASRM |
| October 18 |
New Phase III data on Organon's asenapine presented at the 20th
Annual European Congress of Neuropsychopharmacology in Vienna. |
| October 18 |
ConjuChem Reports Final Results of PC-DAC: Exendin-4 Phase I/II
Multiple-Dose Study for Type 2 Diabetes Confirming Safety and
Efficacy at Once-Weekly Dosing |
| October 18 |
Genta Announces Presentation of New Clinical and Preclinical Data
on Genasense at AACR-NCI-EORTC 'Targets' Conference |
| October 18 |
Molecular Insight Pharmaceuticals, Inc. Announces Positive Results
of Azedra Phase 1 Dosimetry Trial for Neuroendocrine Tumors |
| October 18 |
Access Pharmaceuticals to Present Data on ProLindac at the
AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics'
Conference |
| October 18 |
Initial Results of Phase II Study with HCV Protease Inhibitor
Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate
of Early Virologic Response |
| October 18 |
Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug
Candidate, AL-02, to be Presented at 18th International Symposium
on ALS/MND |
| October 18 |
Surface Logix SLx-4090 Selected Among Top 10 Most Promising
Licensing Candidates In Cardiovascular Disease |
| October 18 |
PTC Therapeutics Announces Additional Results from Phase 2 Study of
PTC124 in Duchenne Muscular Dystrophy |
| October 18 |
Flamel Technologies Announces Positive Results of a Phase I Trial
of FT-105 Basal Insulin versus Lantus |
| October 18 |
Orexigen Therapeutics to Present Data on Contrave and Empatic at
The Obesity Society's 2007 Annual Scientific Meeting |
| October 18 |
Independent Study by Fraunhofer Institute in Germany, Using
Pluristem's PLX Cells, Shows Promise in the Treatment of Ischemic
Stroke |
| October 18 |
Acceleron Pharma's ACE-031 Increases Muscle Mass In a Preclinical
Model of Glucocorticoid-induced Muscle Loss |
| October 18 |
Antibiotics May Not Help Men's Chronic Pelvic Pain: Harvard Doctors
Discuss Alternatives |
| October 18 |
Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic
Area Partnerships Conference |
| October 18 |
Abbott Scientists Create One Molecule With Two Antibody Functions |
| October 18 |
Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics |
| October 18 |
Experts Discuss the Efficacy of the Most Recent Treatments
Available for Psoriasis |
| October 18 |
Japan Institute of Infectious Diseases Publishes Article on
Ampligen as Avian Flu Vaccine Immune Enhancer |
| October 18 |
St. Jude Identifies the Specific Cell That Causes Eye Cancer,
Disproving Long-Held Theory |
| October 18 |
Oral Drug Restores Missing Protein in Boys With MD |
| October 18 |
Immunomedics to Present At the AACR-NCI-EORTC International
Conference |
| October 18 |
SemBioSys confirms commercially viable levels of Native APO AI in
safflower |
| October 19 |
VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta
at AACR-NCI-EORTC International Meeting |
| October 19 |
Actelion Announces Multiple Presentations on Tracleer and the
REVEAL Registry at CHEST 2007 |
| October 19 |
MediciNova Reports Phase IIa Clinical Study Results for MN-305, a
Treatment for Insomnia |
| October 19 |
Pivotal Mircera Study First to Convert Dialysis Patients From
Frequent Dosing Directly to Once Every Two Weeks or Once Every Four
Weeks |
| October 19 |
Data Show Obagi Medical Products' Solubilized Benzoyl Peroxide Gel
May Provide Dramatic Reductions in Acne Lesions Within Four Weeks |
| October 19 |
PAION Sees Continued Development Rationale for Desmoteplase Based
on Findings from Phase III Analysis |
| October 22 |
Results of Pre-Clinical Investigation of Ceragenix's Developmental
Antibiotic to Prevent Sepsis Presented at International Scientific
Meeting |
| October 22 |
Arrive Registry Analysis Demonstrates Continued Safety and Efficacy
of Taxus Stent in Complex Real-World Patients |
| October 22 |
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II
Trial Data for Novel Drug-Eluting Stent System |
| October 22 |
BiPar Announces Upcoming Data Presentations Demonstrating Progress
on PARP Inhibitor Drug Pipeline for Cancer |
| October 22 |
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in
Acute Migraine Headache |
| October 22 |
Schering-Plough Reports Two Phase II Studies of Thrombin Receptor
Antagonist (TRA) Build on Findings from Previous Phase II Study |
| October 22 |
OREXIGEN(TM) Therapeutics Reports Detailed Results of Phase IIb
Trial of Empatic(TM) to Treat Obesity |
| October 22 |
Orexigen Therapeutics Reports a Summary of Results from the Phase
IIb Trial of Contrave to Treat Obesity |
| October 22 |
Can-Fite: CF102 Drug is Effective in Promoting Liver Tissue
Regeneration; Clinical Trials with CF102 in the Treatment of Liver
Cancer are Due to Commence in Early 2008 |
| October 22 |
Boston Scientific's Next-Generation Stent Shows Improved Clinical
Outcomes in Complex Lesions |
| October 22 |
Preliminary Results of Randomized Pilot Study Show Comparable
Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent and
Boston Scientific's Taxus Stent in Patients at High Risk of
Restenosis |
| October 22 |
Boston Scientific Promus and Taxus Stents Continue Strong
Performance in Safety and Efficacy Measures |
| October 22 |
Volcano Sponsors First Study Designed to Determine if IVUS Can
Identify Patients at Risk for Stent Thrombosis and to Demonstrate
the Benefit of IVUS Guidance for Procedural Outcome |
| October 22 |
Abbott's Xience V Everolimus Eluting Coronary Stent Shows Continued
Superiority to Taxus Stent in Reducing Major Adverse Cardiac Events
in Spirit III Clinical Trial |
| October 22 |
Elixir Medical Announces Positive Clinical Results for the
Company's First Drug Eluting Coronary Stent |
| October 22 |
Study Using PARI Nebulizer Finds COPD Therapy of Nebulizer and
Inhaler Combo More Effective than Inhaler Alone |
| October 22 |
Shire to Present New Scientific Data on its ADHD Treatments at a
Major Psychiatric Meeting |
| October 22 |
Positive Five-Year Safety Data for Taxus Stent Reported in Boston
Scientific Trial |
| October 23 |
Micromet is Presenting Four Posters on BiTE Antibodies at the
International AACR-NCI-EORTC Conference |
| October 23 |
NanoViricides, Inc. Presents at the Global Pharma R&D Summit |
| October 23 |
Orexigen Therapeutics Reports Preclinical Results Showing Contrave
Acts on Specific Pathways in the Brain to Reduce Food Intake |
| October 23 |
Abbott Announces Positive One-Year Results from the World's First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent |
| October 23 |
Genaera Corporation Presents Phase 1 Data for Trodusquemine
(MSI-1436) at the North American Association for the Study of
Obesity Annual Meeting |
| October 23 |
Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436)
Data at the North American Association for the Study of Obesity
Annual Meeting |
| October 23 |
EpiCept to Present Preclinical Studies of EPC2407 in Combination
With Anti-Angiogenic and Chemotherpeutic Agents at the
AACR-NCI-EORTC International Conference |
| October 23 |
Genasense Can be Administered by Brief High-Dose IV Infusion |
| October 23 |
Avalon Pharmaceuticals Announces Its Proprietary Drug Discovery and
Development Platform AvalonRx(R) Identifies Potent Selective
Inhibitors for the c-Myc and Beta-catenin Pathways |
| October 23 |
Vanda Pharmaceuticals to Present New Data on Iloperidone at the
2007 American Society of Human Genetics Annual Meeting |
| October 23 |
Micromet Data Presented at the International AACR-NCI-EORTC
Conference Support the Development of Adecatumumab (MT201) in
Earlier Stage Cancer Disease Settings |
| October 23 |
Arius Announces Cancer Stem Cell Antibody Program Successfully
Completes First Toxicology Study |
| October 23 |
Amicus Therapeutics Announces Positive Results From Two Phase 1
Clinical Studies of AT2220 for Pompe Disease |
| October 23 |
Progen Presents Preclinical Data for Second-Generation Anti-Tumor
Compounds at AACR-NCI-EORTC International Conference |
| October 23 |
Copaxone Significantly Decreases Disease Activity in Patients Who
Switched from Interferon Beta (INFb) Due to Development of
Neutralizing Antibodies (NAbs) |
| October 23 |
VIVUS Announces Qnexa Quality of Life Data at the Obesity Society's
2007 Annual Scientific Meeting |
| October 23 |
Sunesis Pharmaceuticals Hosts Conference Call to Discuss
Preliminary SNS-595 Activity in its Ovarian Cancer Clinical Trial
Being Reported at the AACR-NCI-EORTC International Conference |
| October 23 |
Communicating Clinical Trial Data: Timing Remains Key Challenge for
Marketing Teams |
| October 23 |
ZymoGenetics Reports Positive Phase 1 Results for IL-21 With
Nexavar |
| October 23 |
InVitria's Animal Free Lacromin Provides a Cost-Effective
Improvement Over Transferrin |
| October 23 |
Roche Announces Positive Results in Solid Tumors Using Human
Monoclonal Antibody Against IGF-1R (R1507) |
| October 23 |
Tapestry Pharmaceuticals Presents Data on TPI 287 at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics |
| October 23 |
Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor
Efficacy Against Advanced Liver Cancers |
| October 23 |
Cleviprex (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and
Maintained Control in Study of Patients with Acute Hypertension |
| October 24 |
ActivBiotics to Present Results of Pivotal Study in the Treatment
of Peripheral Arterial Disease at AHA Meeting |
| October 24 |
Spectrum Pharmaceuticals Announces Presentation of SPI-1620 Data at
the AACR-NCI-EORTC International Conference |
| October 24 |
Human Genome Sciences Presents New Data Showing Anti-Tumor Activity
And Safety Of Trail Receptor Antibodies In Combination With
Chemotherapy |
| October 24 |
Mersana Therapeutics Reports Phase I Results for XMT-1001 in
Patients with Solid Tumors at AACR-NCI-EORTC International
Conference |
| October 24 |
EntreMed Presents Results for Panzem NCD Phase 2 Ovarian Cancer
Study |
| October 24 |
Anthera Announces Positive Phase II Clinical Results From A-002
Cardiovascular Disease Trial |
| October 24 |
Tranzyme Pharma's Motilin Antagonist TZP-201 Shows Potential for
Preventing and Treating Chemotherapy-Induced Diarrhea (CID) |
| October 24 |
Oncolytics Biotech Inc. Collaborators to Present Positive Interim
Results of U.K. Phase Ia/Ib Combination Reolysin and Radiation
Clinical Trial |
| October 24 |
First New Class of Platinum-Based Chemotherapy Drug Candidates in
30 Years Demonstrate Ability to Kill Tumors Resistant to Currently
Marketed Platinum Drugs |
| October 24 |
OSI Pharmaceuticals Summarizes Data Presented on OSI-906 at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics |
| October 24 |
Phase I Results Announced for R1507 From Genmab's Collaboration
With Roche |
| October 24 |
New Data May Help Guide the Clinical Development of Biomira's
PX-478 and PX-866 |
| October 24 |
Genasense Data in Patients with Advanced Melanoma to be Featured at
4th International Melanoma Congress |
| October 24 |
Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety
Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting |
| October 24 |
CV Therapeutics Announces Presentations at American Heart
Association Scientific Sessions 2007 |
| October 24 |
Updated Phase 1 Data for Exelixis' XL184 Demonstrate
Pharmacodynamic and Clinical Anti-Tumor Activity |
| October 24 |
Tracleer Shows Clinical Benefit as Combination Therapy with
Sildenafil for Pulmonary Arterial Hypertension |
| October 24 |
Access Pharmaceuticals Announces Presentation on ProLindac Phase 2
Study at AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics'
Conference |
| October 24 |
Cephalon Announces Positive Results from Its Pivotal Study of
Treanda in Patients with Non-Hodgkin's Lymphoma |
| October 24 |
New Data Show Improvements in Work Performance in Patients with
Chronic Insomnia Treated with Ambien CR (zolpidem tartrate
extended-release) Tablets CIV |
| October 24 |
Gilead Announces New Letairis (ambrisentan) Data for the Treatment
of Patients with Pulmonary Arterial Hypertension (WHO Group 1) |
| October 24 |
Ascenta Therapeutics Highlights Multiple Data Presentations at This
Week's AACR-NCI-EORTC International Conference in San Francisco |
| October 24 |
Gemin X Presents Mechanism of Action of GMX1778 and Preclinical
Data of its Prodrug GMX1777 |
| October 24 |
Gemin X Identifies Molecules that Inhibit Telomere Maintenance
Proteins Important to Cancer Cell Survival |
| October 24 |
Angiomax / Angiox (bivalirudin) Significantly Improved Net Outcomes
in Heart Attack Patients |
| October 24 |
Inhaled Steriods Used as Preventive Treatment Post 9/11 |
| October 24 |
Nymox Announces Clinical Study Presentation on New BPH Drug at
Upcoming American Urological Association Meeting |
| October 24 |
Safety Profile of Medtronic's Endeavor Drug-Eluting Stent Affirmed
in Comprehensive Data Analysis |
| October 24 |
Active Biotech's Cancer Project ANYARA Proven Safe in Combination
with Taxotere |
| October 24 |
Micromet Data Presented at the International AACR-NCI-EORTC
Conference Support the Development of Adecatumumab (MT201) in
Earlier Stage Cancer Disease Settings |
| October 24 |
Drug Eluting Balloons Show Promise as a Potential Alternative to
Drug Eluting Stents Used in the Treatment of Coronary Artery
Disease |
| October 24 |
New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor
Properties |
| October 24 |
BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity
With BSI-401, Its Second-Generation PARP Inhibitor |
| October 24 |
Stanford/Packard Researchers Find Disease Genes Hidden in Discarded
Data |
| October 25 |
SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary
Session |
| October 25 |
DiaKine Therapeutics' Anti-Diabetes Drug Featured in U.S. Research
Report |
| October 25 |
Synta Presents New Data on Elesclomol (Formerly STA-4783) at
AACR-NCI-EORTC International Conference |
| October 25 |
Bionovo to Present Mechanism of Action Data Regarding BZL101, Its
Anti-cancer Agent, at the American Association of Cancer Research
Conference |
| October 25 |
Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity
in Papillary Renal Cell Cancer |
| October 25 |
Synvista Therapeutics' Alagebrium Shows Potential for use in
Treating Diabetes-Related Gastrointestinal Complications |
| October 25 |
Two Clinical Trials for Nebulized Formoterol Fumarate on Long-Term
and Cardiovascular Safety in Treating COPD |
| October 25 |
Unigene Reports Successful Completion of Oral Calcitonin Human
Study |
| October 25 |
ImmunoGen, Inc. Reports New Clinical and Preclinical Data at
AACR-NCI-EORTC |
| October 25 |
Seattle Genetics Reports Preclinical Data on SGN-40 and an
Anti-CD19 Antibody-Drug Conjugate |
| October 25 |
Alfacell to Host Webinar on RNA Interference-Like Mechanics of
RNase Therapeutics on Nov. 29 |
| October 25 |
Avalon Pharmaceuticals Announces Beta-catenin Pathway Inhibitors
Demonstrate Significant Tumor Growth Inhibition |
| October 25 |
OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-Action
Data Published in Peer-Review Journal |
| October 25 |
Array BioPharma Reports Positive New Data on ErbB-2 / EGFR
Inhibitor, ARRY-543 |
| October 25 |
CuraGen Announces Presentation of Phase I Dose-Escalation Results
on CR011- vcMMAE for Metastatic Melanoma |
| October 25 |
Arqule Announces Clinical and Pre-Clinical Data on Anti-Metastatic
Potential of ARQ 197, a Selective c-Met Inhibitor |
| October 25 |
Curis Announces Presentation at the 2007 AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics |
| October 25 |
Intradigm Study Shows Ability of siRNAs Systemically Delivered With
TargeTran System to Suppress Tumor-Induced Angiogenesis in Mice |
| October 25 |
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference |
| October 25 |
Study Showed Patients Using Copaxone Had Significantly Lower Risk
of Relapse and Lower Medical Costs Compared to Patients Using Rebif
in Relapsing-Remitting Multiple Sclerosis (RRMS) |
| October 25 |
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated
Copaxone is More Cost Effective Than Tysabri for Treatment of
Relapsing-Remitting Multiple Sclerosis |
| October 25 |
Genaera Corporation Provides Highlights of Positive Phase 1
Trodusquemine (MSI-1436) Data from the North American Association
for the Study of Obesity Annual Meeting |
| October 25 |
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor
Demonstrates Synergy with DNA Damaging Agents |
| October 25 |
Clinical Trial Data on the Safety and Efficacy of Concomitant
Formoterol Fumarate/ Tiotropium Treatment for COPD |
| October 25 |
Advanced Cell Presents Phase I(b) Data Demonstrating Safety and
Optimal Dosage for Myoblast Program at TCT Conference and
Exposition |
| October 25 |
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Trofex
Prostate Cancer Data at AACR |
| October 25 |
EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for
ENMD-1198 |
| October 25 |
Novel Alternative Approach to Inhibiting Insulin Growth Factor
(IGF) May Provide New Treatment for Breast Cancer and Other Cancers |
| October 25 |
Brovana Inhalation Solution Study Data Presented at American
College of Chest Physicians Annual Conference |
| October 25 |
Sirion Therapeutics Announces Positive Phase III Results for
Difluprednate |
| October 25 |
Aradigm Corporation Reports Initial Human Data on a Novel Approach
to Treatment of Tobacco Smoking Addiction Using its AERx Essence
Nicotine Inhaler |
| October 25 |
Flamel Technologies Announces Positive Top Line Results of a
Clinical Trial of IFN-alpha-XL versus PegIntron in Patients with
Chronic Hepatitis C Virus Infection |
| October 25 |
Study Shows Vaprisol is Effective in Increasing Serum Sodium Levels
and Well-Tolerated in Patients With Euvolemic or Hypervolemic
Hyponatremia |
| October 25 |
Final Gemini Study Results Confirm Boosted Invirase Was as
Effective as Kaletra While Providing an Improved Triglyceride
Profile for HIV Patients |
| October 25 |
Advanced Cell Presents Phase I(b) Data Demonstrating Safety and
Optimal Dosage for Myoblast Program at TCT Conference and
Exposition |
| October 25 |
Results of Vyvanse (lisdexamfetamine dimesylate) Pivotal Trial in
Adult ADHD Presented at Major Scientific Meeting |
| October 25 |
Arius Announces New Findings in Trop-2 and CD59 CANCER Antibody
Programs |
| October 25 |
EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal
Cell Cancer Model |
| October 25 |
Long-Term 12-Month Safety Data Presented on ADHD Patch Daytrana
(methylphenidate transdermal system) |
| October 25 |
ANX-514 Reduces Hypersensitivity Reactions Without Impacting
Pharmacokinetics or Antitumor Activity in Preclinical Tests |
| October 25 |
BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1
Gene in Multiple Cancer Types |
